This is particularly relevant for immunotherapies that target liver tissue, e.g., hepatocellular carcinoma, to overcome intrinsic liver- as well as tumor-induced tolerance and to elicit antigen-specific effector CD4+ and CD8+ T cells collectively contribute to successful therapies. The gene discussed is CD8A; the disease is hepatocellular carcinoma.